Combining botulinum toxin and phenol to manage spasticity in children.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15241761.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To describe the specific techniques and adverse reactions of using concurrent, multiple injections of both botulinum toxin and phenol to manage spasticity in children with cerebral palsy (CP) and other neurologic conditions. A retrospective case series. A tertiary care children's hospital. Consecutive patients (N=68) with spasticity related to CP or other neurologic conditions. Ninety injection sessions combining botulinum toxin and phenol to manage spasticity. Documentation of adverse reactions. The mean phenol dosage was 9.5mL at a mean of 0.6mL/kg per injection dose. The mean botulinum toxin type A (Botox) dose injected was 193U (12U/kg), and the mean of botulinum toxin type B (Myobloc) dose injected was 7750U (530U/kg). The mean number of muscles injected was 14. Adverse reactions are described but were infrequent. Dysesthetic hand pain occurred in 2 patients. One patient developed a systemic reaction to Myobloc. Using botulinum toxin and phenol injections allowed many muscles to be injected to manage spasticity in children with CP and other neurologic conditions. Using this combination allowed an increased number of injections at the maximal recommended dose.
Medical subject headings
- Botulinum Toxins, Type A
- Cerebral Palsy
- Neuromuscular Agents
- Phenol